Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 2, 2012, Pages 159-166

  Barrios, Vivencio ^a   Coca, Antonio ^b   Escobar, Carlos ^c   Enrique, Rosa ^d   Rincón, Luis Miguel ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d Sant Joan Despi   (Spain)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Clinical practice; Reninangiotensin system; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL PRACTICE; COMORBIDITY; DIABETIC NEPHROPATHY; ESSENTIAL HYPERTENSION; HEALTH SURVEY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; ORGAN INJURY; OUTPATIENT; REVIEW; SIDE EFFECT;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84856623560     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.185     Document Type: Review

References (25)

1. Barrios V, Escobar C, Echarri R, de Alvaro F. New therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartan. In: Hot Topics in Hypertension Vol. 2, Issue 8. Volpe M (Ed.).FBCommunication, Modena, Italy, 1-24 (2009).
2. Volpe M. Angiotensin II: an amplifier of cardiovascular risk. Curr. Hypertens. Rep. 6, 247-248 (2004).
3. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J. Hypertens. 21, 1429-1443 (2003). (Pubitemid 36994116)
4. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369, 1208-1219 (2007). (Pubitemid 46527856)
5. Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin. Pharmacother. 9, 129-136 (2008). (Pubitemid 351233754)
6. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008). (Pubitemid 351522739)
7. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002). (Pubitemid 34286536)
8. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033-1041 (2001).
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
10. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003). (Pubitemid 37093919)
11. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45, 198-202 (2005). (Pubitemid 40179960)
12. Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with losartan at all stages of Type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. 15, 3117-3125 (2004). (Pubitemid 39578844)
13. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. 351, 1952-1961 (2004). (Pubitemid 39447136)
14. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105-1187 (2007). (Pubitemid 46924065)
15. Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Caldern A. Sex differences in the hypertensive population with chronic ischemic heart disease. J. Clin. Hypertens. (Greenwich) 10, 779-786 (2008).
16. Barrios V, Escobar C, Divisn JA, Medialdea F. Clinical experience with a low dose fixed combination of perindopril plus indapamide in a primary-care setting: the PRETEND study. Therapy 4, 677-683 (2007). (Pubitemid 47578196)
17. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892 (2000). (Pubitemid 30419054)
18. Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med. 167, 68-73 (2007). (Pubitemid 46072409)
19. Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Caldern A. Risk factor control in the hypertensive patients with chronic ischemic heart disease attended in cardiologic outpatient clinics. The CINHTIA study. Rev. Clin. Esp. 208, 400-404 (2008).
20. Neutel JM. Choosing among renin- angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr. Med. Res. Opin. 26, 213-222 (2010).
21. Barrios V, Escobar C, Prieto L, Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet 372, 535-536 (2008).
22. Cleland JG. Role of angiotensin receptor blockers in the treatment of chronic heart failure: what do the clinical practice guidelines say? Rev. Esp. Cardiol. 6(Suppl. C), 58-72 (2006).
23. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 148, 16-29 (2008). (Pubitemid 351664943)
24. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115, 41-46 (2003). (Pubitemid 36831120)
25. Barrios V, Escobar C, Caldern A, Echarri R, Barrios S, Navarro-Cid J. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. J. Renin Angiotensin Aldosterone Syst. 10, 168-173 (2009).